BSP:I1NC34 (USA)  
Incyte Corp logo

Incyte Corp

R$ 193.00 (0%) Dec 6
On watch
P/E:
21.00
P/B:
4.34
Market Cap:
R$ 85.88B ($ 16.46B)
Enterprise V:
R$ 81.51B ($ 15.63B)
Volume:
-
Avg Vol (2M):
10.00
Also Trade In:
Volume:
-
Market Cap R$:
85.88B
Market Cap $:
16.46B
PE Ratio:
21.00
Avg Vol (2-Month):
10.00
Enterprise Value R$:
81.51B
Enterprise Value $:
15.63B
PB Ratio:
4.34

Business Description

Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Name Current Vs Industry Vs History
Cash-To-Debt 70.75
Equity-to-Asset 0.77
Debt-to-Equity 0.01
Debt-to-EBITDA 0.07
Interest Coverage 219.06
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 10.03
Distress
Grey
Safe
Beneish M-Score -2.15
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 99.98
9-Day RSI 99.17
14-Day RSI 95.17
6-1 Month Momentum % 2.19
12-1 Month Momentum % 3.8

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.8
Quick Ratio 3.75
Cash Ratio 2.96
Days Inventory 70.46
Days Sales Outstanding 65.67
Days Payable 303.54

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.2